Compare FuelCell Energy Inc (FCEL) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs Tango Therapeutics Inc. — how do they compare? FuelCell Energy Inc trades at $13.96 (market cap $1.24B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 3× FuelCell Energy Inc's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, FuelCell Energy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold FuelCell Energy Inc for 48 Days and Tango Therapeutics Inc. for 0 Days on average.
| FCEL | TNGX | |
|---|---|---|
Market Cap | $1.24B | $3.75B |
Volume | 7,483,477 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $36.01 | $32.90 |
52-Week Low | $6.00 | $7.50 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $818.79M | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FuelCell Energy (FCEL) trades at $14.16, down 13.5% over 24 hours, reflecting negative momentum amid ongoing operational losses. The stock exhibits a bearish technical signal, with key support at $14. Recent financials show revenue of $158.16M in 2025 but a net loss of $187.90M, with negative gross and net income margins. Analyst consensus is split evenly between Buy and Hold, with a $21.57 price target. Multiple law firms have announced securities class actions related to disclosures from June to September 2026, adding legal overhangs.
FCEL's outlook remains challenged by persistent unprofitability and cash burn, though analyst targets suggest potential upside from current levels. Key risks include the class action lawsuits, execution on scaling power agreements, and the company's ability to achieve positive cash flow. The stock presents a high-risk opportunity contingent on operational turnaround and resolution of legal issues.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
